SLC5A2 and type 2 diabetes mellitus: A meta-analysis42 showed that sodium-glucose cotransporter 2 (SGLT-2) inhibitors might potentially prevent gout-related events in patients with type 2 diabetes mellitus, and recent studies43,44 have shown a reduction in blood uric acid levels in diabetic patients on glucose-lowering drugs.